329 related articles for article (PubMed ID: 28442891)
1. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.
Venur VA; Joshi M; Nepple KG; Zakharia Y
Drug Des Devel Ther; 2017; 11():1175-1182. PubMed ID: 28442891
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
Joseph RW; Chatta G; Vaishampayan U
Urol Oncol; 2017 Apr; 35(4):142-148. PubMed ID: 28259541
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Motzer RJ; Rini BI; McDermott DF; Redman BG; Kuzel TM; Harrison MR; Vaishampayan UN; Drabkin HA; George S; Logan TF; Margolin KA; Plimack ER; Lambert AM; Waxman IM; Hammers HJ
J Clin Oncol; 2015 May; 33(13):1430-7. PubMed ID: 25452452
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab in the treatment of advanced renal cell carcinoma.
Arasaratnam M; Gurney H
Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
[TBL] [Abstract][Full Text] [Related]
7. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
8. A review of checkpoint inhibitors in the management of renal cell carcinoma.
Hanna KS
J Oncol Pharm Pract; 2020 Mar; 26(2):445-458. PubMed ID: 31631812
[TBL] [Abstract][Full Text] [Related]
9. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Therapy in Renal Cell Carcinoma.
Lee CH; Motzer RJ
Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
[TBL] [Abstract][Full Text] [Related]
12. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Choueiri TK; Fishman MN; Escudier B; McDermott DF; Drake CG; Kluger H; Stadler WM; Perez-Gracia JL; McNeel DG; Curti B; Harrison MR; Plimack ER; Appleman L; Fong L; Albiges L; Cohen L; Young TC; Chasalow SD; Ross-Macdonald P; Srivastava S; Jure-Kunkel M; Kurland JF; Simon JS; Sznol M
Clin Cancer Res; 2016 Nov; 22(22):5461-5471. PubMed ID: 27169994
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
George S; Motzer RJ; Hammers HJ; Redman BG; Kuzel TM; Tykodi SS; Plimack ER; Jiang J; Waxman IM; Rini BI
JAMA Oncol; 2016 Sep; 2(9):1179-86. PubMed ID: 27243803
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.
de Velasco G; Miao D; Voss MH; Hakimi AA; Hsieh JJ; Tannir NM; Tamboli P; Appleman LJ; Rathmell WK; Van Allen EM; Choueiri TK
Cancer Immunol Res; 2016 Oct; 4(10):820-822. PubMed ID: 27538576
[TBL] [Abstract][Full Text] [Related]
17. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in renal cell carcinoma.
Ross K; Jones RJ
Clin Sci (Lond); 2017 Nov; 131(21):2627-2642. PubMed ID: 29079639
[TBL] [Abstract][Full Text] [Related]
19. Advances in treatment of metastatic renal cell carcinoma.
Gong J; Gerendash B; Dizman N; Khan A; Pal SK
Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
[TBL] [Abstract][Full Text] [Related]
20. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
[Next] [New Search]